Loading provider…
Loading provider…
Rheumatology Physician in Tujunga, CA
NPI: 1437178274Primary Practice Location
Dan La MD Inc
6673 W Foothill Blvd, Tujunga, CA
Primary Employer
Dan La MD Inc
mobile.foothillarthritisclinic.com
HQ Phone
Get MD Dan's Phone Numberphone_androidMobile
Get MD Dan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2003 - 2025

American Board of Internal Medicine
Rheumatology
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Fellowship • Rheumatology
2004 - 2006
Residency • Internal Medicine
2001 - 2004
Other
Medical School
Until 2001
American University of the Caribbean School of Medicine
Medical School
Until 2001
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 720 | 2,053 |
| 2 | 96401Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 152 | 447 |
| 3 | 20611Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | 102 | 377 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 91 | 91 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 67 | 86 |
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: A p...
Authors: Clio P. Mavragani, Dan T La, William Stohl, Mary K. Crow
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
Authors: William Stohl
Publication Date: 2010-02
Testicular distribution and toxicity of a novel LTA4H inhibitor in rats.
Authors: Ward, P D, La, D
Journal: Toxicol Appl Pharmacol
Publication Date: 2014-04-22
Lead Sponsor: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: BENLYSTA, OTHER: SLE treatment
Lead Sponsor: Amgen
Intervention / Treatment: BIOLOGICAL: Pegloticase with MTX
Lead Sponsor: Anika Therapeutics, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Cingal, DRUG: Triamcinolone Hexacetonide (TH)